Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs @DanaFarber @MassGenBrigham: more RA flares but similar mortality, severe irAEs rates Give them what they need! ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG

Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu

• Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung…

Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg https://t.co/QtclWIWAw9 Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt

• A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis - ACR Meeti…

Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h

• Burden of Disease in Refractory Rheumatoid Arthritis - ACR Meeting Abstracts

Systemic Inflammation Index (neutrophils*platelet count/lymphocyte count) predicts survival in RA in 1000+ pts All cause mortality OR 2.64 CV-mortality OR 3.03 Another proof (if needed) of asso inflammation & mortality in RA https://t.co/A77iPTTfTM Abs#1650 #ACR22 @RheumNow https://t.co/8aHYAZEg6v

• Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortali…

Tuttle et al. Phase 2 RCT of Peresolimab (PD-1 stimulator) in DMARD-IR RA. Evidence of efficacy. No new safety signals @RheumNow #ACR22 Abstr#L03 https://t.co/vhrmtGTjw1 https://t.co/k1LLk95bv1

• A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis - ACR Meeti…

Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX

• Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs In…

FORWARD databank RA 4500+ opioid & 11000+ NSAID MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY) Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY) IR MACE & mortality NSAID < Opioids Driven by VTE > Opioids vs NSAIDs HR=2.45 https://t.co/fl7cJNGrvu Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl

• Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs In…